Squamous cell carcinoma-associated antigens used in novel strategies for the detection and treatment of minimal residual head and neck cancer

Anticancer Research

Volumn 16, Issue 4 C, 1996, Pages 2409-2413

  Van Dongen, Guus A M S ^a   Brakenhoff, Ruud M ^a   Ten Brink, Corlinda ^a   Van Gog, Frank B ^a   De Bree, Remco ^a   Ouak, Jasper J ^a   Snow, Gordon B ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adjuvant therapy monoclonal antibodies; Head and neck squamous cell carcinoma; Minimal residual disease; Reverse transcriptase polymerase chain reaction; Tumour detection

Indexed keywords

MONOCLONAL ANTIBODY;

ANTIGEN DETECTION; ARTICLE; BLOOD; BONE MARROW; CANCER CELL; CANCER STAGING; HEAD AND NECK CANCER; HUMAN; IMAGE ANALYSIS; IMMUNOCYTOCHEMISTRY; LYMPH NODE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM METASTASIS; NEOPLASM, RESIDUAL; RADIOIMMUNOTHERAPY; SERPINS;

EID: 0029810485     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Zarbo RJ and Crissman JD: The surgical pathology of head and neck cancer. Semin Oncol 15: 10-19, 1988.
2. Boring CC, Squires TS, Tong T and Montgomery S: Cancer statistics 1994. CA Cancer J Clin 44: 7-26, 1994.
3. Choksi AJ, Dimery IW and Hong WK: Adjuvant chemotherapy of head and neck cancer: the past, the present and the future. Semin Oncol 15: 45-59, 1988.
4. Zbaren P and Lehmann W: Frequency and sites of distant metastases in head and neck squamous cell carcinoma: Arch Otolaryngol Head Neck Surg 113: 762-764, 1987.
5. Cook JA, Jones AS, Phillips DE and Soler Lluch E: Implications of tumor in resection margins following surgical treatment of squamous cell carcinoma of the head and neck. Clin Otolaryngol 18: 37-41, 1993.
6. Vokes EE, Weiselbaum RR, Lippman SM and Hong WK: Head and neck cancer: N Engl J Med 328: 184-194, 1993.
7. Quak JJ, Balm AJM, Van Dongen GAMS, Brakkee JGP, Scheper RJ, Snow GB and Meijer CJLM: A 22 kDa surface antigen detected by monoclonal antibody E48 is exclusively expressed in stratified and transitional epithelia. Am J Pathol 136: 191-197, 1990.
8. Schrijvers AHGJ, Ouak JJ, Uyterlinde AM, Van Walsum M, Meijer CJLM, Snow GB and Van Dongen GAMS: MAb U36, a novel monoclonal antibody successful in immunotargeting squamous cell carcinoma of the head and neck. Cancer Res 53: 4383-4390, 1993.
9. De Bree R, Roos JC, Ouak JJ, Den Hollander W, Snow GB and Van Dongen GAMS: Clinical screening of monoclonal antibodies 323/A3, cSF-25 and K928 for suitability of targeting tumors in the upper aerodigestive and respiratory tract. Nucl Med Commun 15: 613-627, 1994.
10. 99mTc-labeled monoclonal antibody E48 IgG or F(ab')2. J Nucl Med 35: 775-783, 1994.
11. De Bree R, Roos JC, Quak JJ, Den Hollander W, Snow GB and Van Dongen GAMS: Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res 1: 591-598, 1995.
12. Brakenhoff RH, Gerretsen M, Knippels ECM, Van Dijk M, Van Essen H, Olde Weghuis D, Sinke R, Snow GB and Van Dongen GAMS: The human E48 antigen, highly homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell-cell adhesion. J Cell Biol 129: 1677-1689, 1995.
13. Mesker WE, Van den Burg MJM, Oud PS, Knepfle CFHM, Ouwerkerk-Van Velzen MCM, Schipper NW and Tanke HJ: Detection of immunocytochemically stained rare events using image analysis. Cytometry 17: 209-215, 1994.
14. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki J and Riethmuller G: Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85: 1419-1424, 1993.
15. Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, Koch WM, Goodman SN and Sidransky D: Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 332: 429-435, 1995.
16. Gamel JW and Jones AS: Squamous cell carcinoma of the head and neck: cured fraction and median survival time as function of age, sex, histologic type and node status. Br J Cancer 67: 1071-1075, 1993.
17. Leemans CR, Tiwari R, Nauta JJP, Van der Waal I and Snow GB: Regional lymph node involvement and its significance in the development of distant metastases in head and neck cancer. Cancer 71: 452-456, 1993.
18. Van den Brekel MWM, Stel HV, Van der Valk P, Van der Waal I, Meijer CJLM and Snow GB: Micrometastases from squamous cell carcinoma in neck dissection specimens. Eur Arch Otorhinolaryngol 249: 349-353, 1992.
19. Lindemann F, Schlimok G, Dirschedl P, Witte J and Riethmüller G: Prognostic significance of micrometastatic tumor cells in bone marrow of colorectal cancer. Lancet 340: 685-689, 1992.
20. Smith B, Selby P, Southgate J, Pittman K, Bradley C and Blair GE: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338: 1227-1229, 1991.
21. Berinstein NL, Reis MD, Ngan BY, Sawka CA, Jamal HH and Kuzniar B: Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early-stage and advanced-stage follicular lymphoma. J Clin Oncol 11: 1344-1352, 1993.
22. Gerhard M, Juhl H, Kalthoff H, Schreiber HW, Wagener C and Neumaier M: Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 12: 725-729, 1994.
23. Martiat P, Maisin D, Philippe M, Ferrant A, Michaux JL, Cassiman JJ, Van den Berghe H and Sokal G: Detection of residual BCR/ABL transcripts in chronic myeloid leukaemia patients in complete remission using the polymerase chain reaction and nested primers. Brit J Haematol 75: 355-358, 1990.
24. Moreno JG, Croce CM, Fischer R, Monne M, Vihko P, Mulholland SG and Gomella LG: Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 52: 6110-6112, 1992.
25. Burchill SA, Bradbury MF, Pittman K, Southgate J, Smith B and Selby P: Detection of epithelial cancer cells in peripheral blood by reverse transcriptase-polymerase chain reaction . Brit J Cancer 71: 278-281, 1995.
26. Kaufmann DM, Goerner R, Costa SD, Kaul S and Bastert G: Detection of tumor cells in hone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol 10: 1534-1539, 1992.
27. Mansi JL, Easton D, Berger U, Gazet JC, Ford HT, Dearnaley D and Coombes RC: Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years follow-up. Eur J Cancer 27: 1552-1555, 1991.
28. Schlimok G, Funke I, Pantel K, Strobel F, Lindemann F, Witte J and Riethmuller G: Micrometastatic tumor cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. Eur J Cancer 27: 1461-1465, 1991.
29. Wollenberg B, Ollesch A, Maag K Funke I and Wilmes E: Mikrometastasen im knockenmark von patienten mit karzinomen des kopf-hals-bereiches. Laryngo-Rhino-Otol 73: 88-93, 1994.
30. Schoenfeld A, Luqmani Y, Smith D, O'Reilly S, Shousha S, Sinnett HD and Coombes RC: Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res 54: 2986-2990, 1994.
31. Traweek ST, Liu J and Battifora H: Keratin gene expression in non-epithelial tissues: detection with polymerase chain reaction. Am J Pathol 142: 1111-1118, 1993.
32. Dalta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH and Roth MS: Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 12: 475-482, 1994.
33. De Bree R, Roos JC, Quak JJ, Den Hollander W, Wilhelm AJ, Van Lingen A, Snow GB and Van Dongen GAMS: Biodistribution of radiolabeled monoclonal antibody E48 IgG and F(ab')2 in patients with head and neck cancer. Clin Cancer Res 1: 277-286, 1995.
34. 3 chelate for radioimmunotherapy of cancer: a technical protocol: J Nucl Med 34: 1953-1963, 1993.
35. 186Re-labeled monoclonal antibody E48 IgG mediated therapy of human head and neck squamous cell carcinoma xenografts: Cancer Res 53: 3524-3529, 1993.
36. 186Re-labeled MAh E48 IgG. Cell Biophys 24: 135-142, 1994.
37. Chatal J-F, Saccavini J-C, Gestin J-F, Thredez P, Curtet C, Kremer M, Guerreau D, Nolibe D, Fumoleau P and Guillard Y: Redistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas. Cancer Res 49: 3087-3094, 1989.
38. Williams LE, Bares RB, Fass J, Hauptmann S, Schumpelick V and Buell U: Uptake of radiolabeled anti-CEA antibodies in human colorectal primary tumors as a function of tumor mass. Eur J Nucl Med 20: 345-347, 1993.
39. Hird V, Maraveyas A, Snook D, Dhokia B, Soutter WP, Meares C, Stewart JSW, Mason P, Lambert HE and Epenetos AA: Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 68: 403-406, 1993.
40. Jacobs AJ, Fer M, Su FM, Breitz H, Thompson J, Goodgold H, Cain J. Heaps J and Weiden P: A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: Toxicity and clinical response. Obstet Gynecol 82: 586-593, 1993.
41. Crippa F, Bolis G, Seregni E, Gavoni N, Scarfone G, Ferraris C, Buraggi GL and Bombardieri E: Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody 1-131 MOv18: Clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer 31A: 686-690, 1995.